Advertisement

International Cancer Conference Journal

, Volume 8, Issue 4, pp 170–174 | Cite as

Remarkable effect of presurgical nivolumab on originally inoperable papillary renal cell carcinoma with tumor thrombus in inferior vena cava

  • Tomochika Shinagawa
  • Hideaki ItoEmail author
  • Yasuhiro Sakai
  • Shuji Mikami
  • Hideki Oe
  • Minekatsu Taga
  • Osamu Yokoyama
Case report
  • 9 Downloads

Abstract

For the long-term survival of a patient with renal cell carcinoma and a vena cava tumor thrombus, total resection is desired: inoperable patients are sometimes treated with drugs. The effect of the presurgical use of nivolumab, an anti-programmed cell death 1 (PD-1) antibody drug, has been described. Our patient had inoperable renal cancer with an inferior vena cava tumor thrombus. We were able to downsize the tumor to operable size by administrating nivolumab. The patient underwent a nephrectomy and thrombectomy safely. Pathological findings revealed papillary renal cell carcinoma type 2. No viable cells were identified in the removed thrombus. Anti-programmed cell death ligand 1 was expressed on the cell membrane in approximately 20% of the tumor cells, and PD-1 positive tumor-ifiltrating immune cells had infiltrated particularly at the edge of the tumor. This case indicates the positive effect of the presurgical use of nivolumab for advanced papillary renal cell carcinoma.

Keywords

Renal cancer Nivolumab Presurgical Papillary renal cell carcinoma 

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest.

Ethical approval

It was deemed to be unnecessary for this report.

Informed consent

Informed consent was obtained from the patient.

References

  1. 1.
    Blute ML, Leibovich BC, Lohse CM et al (2004) The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 94:33–41CrossRefGoogle Scholar
  2. 2.
    Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813.  https://doi.org/10.1056/NEJMoa1510665 CrossRefGoogle Scholar
  3. 3.
    Karnes RJ, Blute ML (2008) Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol 5:329–339CrossRefGoogle Scholar
  4. 4.
    Powles T, Albiges L, Staehler M et al (2017) Updated European Association of Urology guidelines recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol.  https://doi.org/10.1016/j.eururo.2017.11.016 Google Scholar
  5. 5.
    Choueiri TK, Fay AP, Gray KP et al (2014) PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25:2178–2184CrossRefGoogle Scholar
  6. 6.
    Thompson RH (2006) Tumor B7–H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66:3381–3385CrossRefGoogle Scholar
  7. 7.
    Topalian Suzanne L, Stephen Hodi F et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465CrossRefGoogle Scholar
  8. 8.
    Geynisman DM (2015) Anti-programmed cell death protein 1 (PD-L1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid rhabdoid features. Eur Urol 68:912–914CrossRefGoogle Scholar
  9. 9.
    Ruiz-Bañobre J, Anido U, Abdulkader I et al (2016) Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: a case report. Front Oncol 6:250 (eCollection 2016) CrossRefGoogle Scholar
  10. 10.
    Adrianzen Herrera DA, Fleisig SB, Gartrell BA (2017) Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: on-label but without evidence. Investig New Drugs 35:665–668CrossRefGoogle Scholar
  11. 11.
    Koshkin VS, Barata PC, Zhang T et al (2018) Clinical activity of nivolmab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer 6:9.  https://doi.org/10.1186/s40425-018-0319-9 CrossRefGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Department of UrologyUniversity of FukuiEiheijiJapan
  2. 2.Division of Diagnostic Pathology/Surgical PathologyUniversity of FukuiEiheijiJapan
  3. 3.Department of Diagnostic PathologyFujita Health University School of MedicineToyoakeJapan
  4. 4.Department of Diagnostic PathologyKeio University School of MedicineTokyoJapan

Personalised recommendations